Matinas BioPharma's market cap is currently ―. The company's EPS TTM is $-0.105; its P/E ratio is -1.80; Matinas BioPharma is scheduled to report earnings on May 8, 2024, and the estimated EPS forecast is $-0.03. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	-	-	$ 1.10M	$ 1.06M	$ 1.06M
Gross Profit	-	-	$ 1.10M	$ 1.06M	-
EBIT	$ -6.05M	$ -6.06M	$ 7.85M	$ -3.63M	$ -5.46M
EBITDA	$ -5.80M	$ -5.80M	$ 8.12M	$ -3.82M	$ -5.23M
Net Income Common Stockholders	$ -6.05M	$ -6.06M	$ 7.85M	$ -3.63M	$ -5.46M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 18.22M	$ 22.56M	$ 24.91M	$ 28.81M	$ 33.05M
Total Assets	$ 29.79M	$ 34.02M	$ 38.26M	$ 44.82M	$ 47.55M
Total Debt	$ 3.71M	$ 3.85M	$ 3.99M	$ 4.12M	$ 4.23M
Net Debt	$ -14.51M	$ -18.71M	$ -20.92M	$ -24.69M	$ -28.82M
Total Liabilities	$ 6.64M	$ 6.17M	$ 5.64M	$ 8.18M	$ 8.93M
Stockholders Equity	$ 23.15M	$ 27.85M	$ 32.63M	$ 36.64M	$ 38.62M
Cash Flow	-
Free Cash Flow	$ -4.43M	$ -2.40M	$ -4.09M	$ -4.34M	$ -5.22M
Operating Cash Flow	$ -4.42M	$ -2.19M	$ -4.09M	$ -4.30M	$ -4.97M
Investing Cash Flow	$ 1.08M	$ 6.20M	$ 3.00M	$ -42.01K	$ 5.75M
Financing Cash Flow	$ -1.00K	$ -1.00K	$ -4.00K	$ -4.64K	$ -3.65K

Currency in USD

Matinas BioPharma Earnings and Revenue History

Income Statement >

Matinas BioPharma Debt to Assets

Balance Sheet >

Matinas BioPharma Cash Flow

Cash Flow >

Matinas BioPharma Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing